View More Recent Stories
-
Celcuity (CELC) Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy
-
Celcuity (CELC) Reports In-Line Q3 EPS
-
Celcuity Inc (CELC) PT Raised to $42 at Stifel
-
TD Cowen Reiterates Buy Rating on Celcuity Inc (CELC)
-
Celcuity Inc (CELC) PT Lowered to $39 at Stifel
-
Celcuity (CELC) Tops Q2 EPS by 10c
-
Celcuity Inc (CELC) PT Lowered to $68 at Jefferies

